Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190290310 | Cervix | CC | regulation of supramolecular fiber organization | 92/2311 | 383/18723 | 1.49e-10 | 2.48e-08 | 92 |
GO:004325410 | Cervix | CC | regulation of protein-containing complex assembly | 96/2311 | 428/18723 | 2.91e-09 | 3.05e-07 | 96 |
GO:005125810 | Cervix | CC | protein polymerization | 70/2311 | 297/18723 | 5.20e-08 | 3.11e-06 | 70 |
GO:004348410 | Cervix | CC | regulation of RNA splicing | 42/2311 | 148/18723 | 1.25e-07 | 6.24e-06 | 42 |
GO:003227110 | Cervix | CC | regulation of protein polymerization | 57/2311 | 233/18723 | 2.37e-07 | 1.03e-05 | 57 |
GO:19033119 | Cervix | CC | regulation of mRNA metabolic process | 64/2311 | 288/18723 | 1.71e-06 | 5.64e-05 | 64 |
GO:003311910 | Cervix | CC | negative regulation of RNA splicing | 13/2311 | 25/18723 | 1.83e-06 | 5.89e-05 | 13 |
GO:00485118 | Cervix | CC | rhythmic process | 65/2311 | 298/18723 | 2.79e-06 | 8.04e-05 | 65 |
GO:19029048 | Cervix | CC | negative regulation of supramolecular fiber organization | 40/2311 | 167/18723 | 2.39e-05 | 4.17e-04 | 40 |
GO:004802410 | Cervix | CC | regulation of mRNA splicing, via spliceosome | 28/2311 | 101/18723 | 2.41e-05 | 4.19e-04 | 28 |
GO:00313339 | Cervix | CC | negative regulation of protein-containing complex assembly | 35/2311 | 141/18723 | 3.41e-05 | 5.55e-04 | 35 |
GO:00181057 | Cervix | CC | peptidyl-serine phosphorylation | 63/2311 | 315/18723 | 6.65e-05 | 9.47e-04 | 63 |
GO:00076238 | Cervix | CC | circadian rhythm | 46/2311 | 210/18723 | 6.76e-05 | 9.60e-04 | 46 |
GO:007233110 | Cervix | CC | signal transduction by p53 class mediator | 38/2311 | 163/18723 | 7.06e-05 | 9.85e-04 | 38 |
GO:00106399 | Cervix | CC | negative regulation of organelle organization | 68/2311 | 348/18723 | 7.40e-05 | 1.03e-03 | 68 |
GO:00182096 | Cervix | CC | peptidyl-serine modification | 66/2311 | 338/18723 | 9.58e-05 | 1.25e-03 | 66 |
GO:00506849 | Cervix | CC | regulation of mRNA processing | 33/2311 | 137/18723 | 1.06e-04 | 1.35e-03 | 33 |
GO:00514948 | Cervix | CC | negative regulation of cytoskeleton organization | 37/2311 | 163/18723 | 1.57e-04 | 1.88e-03 | 37 |
GO:20010209 | Cervix | CC | regulation of response to DNA damage stimulus | 46/2311 | 219/18723 | 1.92e-04 | 2.23e-03 | 46 |
GO:190331210 | Cervix | CC | negative regulation of mRNA metabolic process | 24/2311 | 92/18723 | 2.49e-04 | 2.77e-03 | 24 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DYRK1A | SNV | Missense_Mutation | novel | c.938N>T | p.Gln313Leu | p.Q313L | Q13627 | protein_coding | tolerated(0.34) | benign(0.347) | TCGA-85-8070-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
DYRK1A | SNV | Missense_Mutation | novel | c.373N>A | p.Asp125Asn | p.D125N | Q13627 | protein_coding | tolerated(0.05) | benign(0.098) | TCGA-85-A4QQ-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
DYRK1A | insertion | Frame_Shift_Ins | novel | c.1932_1933insA | p.Ser645IlefsTer30 | p.S645Ifs*30 | Q13627 | protein_coding | | | TCGA-55-A48X-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
DYRK1A | SNV | Missense_Mutation | novel | c.1785N>C | p.Gln595His | p.Q595H | Q13627 | protein_coding | tolerated_low_confidence(0.1) | benign(0) | TCGA-CN-4723-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
DYRK1A | SNV | Missense_Mutation | novel | c.234G>T | p.Gln78His | p.Q78H | Q13627 | protein_coding | deleterious(0.02) | benign(0.003) | TCGA-CN-6010-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
DYRK1A | SNV | Missense_Mutation | | c.739G>A | p.Asp247Asn | p.D247N | Q13627 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-CR-5248-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | PD |
DYRK1A | SNV | Missense_Mutation | novel | c.1360N>C | p.Asp454His | p.D454H | Q13627 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-CV-6938-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
DYRK1A | SNV | Missense_Mutation | | c.478G>C | p.Glu160Gln | p.E160Q | Q13627 | protein_coding | deleterious(0.03) | benign(0.287) | TCGA-F7-8489-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
DYRK1A | SNV | Missense_Mutation | novel | c.506C>T | p.Ser169Phe | p.S169F | Q13627 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-P3-A6T2-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
DYRK1A | SNV | Missense_Mutation | | c.538G>A | p.Val180Met | p.V180M | Q13627 | protein_coding | tolerated(0.07) | benign(0.205) | TCGA-EJ-5510-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme1WO2011135259 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme15-1 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme6Pyrrolo[2,3-d]pyrimidines | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme23MPPDerivatives | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | inhibitor | 249565842 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme13INDY | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | inhibitor | 405560505 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme4Upper | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme12-3 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme18 | | |